While the activation of the proto-oncogenes has been implicated in the development and progression of cancer of many tissues, the role of oncogenes in the development of oesophageal adenocarcinoma has not been defined. Fifteen patients who had undergone resection for oesophageal adenocarcinoma and 15 who had undergone oesophagectomy or biopsy for Barrett's oesophagus were studied. The latter patients also had adjacent normal gastric mucosa biopsied for comparison with the metaplastic oesophageal mucosa. The mucosal samples were snap frozen and subsequently stained with monoclonal antibodies to the following oncogene associated proteins; c-erbB2 (neu and CE-1) (external domain), cerbB2 (NCL-CB11) (internal domain), c-src, c-ras, c-myc, c-fos, c-jun, and the oncosuppressor gene -p53. All tumours were well or moderately differentiated adenocarcinomas arising from the lower third of the oesophagus. Eleven specimens showed strong membraneous staining with both c-erbB2 (neu) and c-erbB2 (CBL-CBll). Seven specimens showed strong nuclear staining with p53 oncosuppressor gene. Three specimens were positive for c-ras and c-src, and two were positive for c-jun. In Barrett's epithelium, nine specimens were positive for c-erbB2 (neu and CBII), three were positive for c-src, two were positive for c-ras and c-jun, and one was positive for c-fos. Two of the gastric mucosal biopsy specimens expressed c-erbB2 weakly but no other oncogenes were found. The frequency of positive staining for c-erbB2 is very high, compared with the expression of these genes in other tumours. It is also concluded that errors in the onco-suppressor gene p53, and especialiy in the external and internal domains of c-erbB2, which is also often expressed in Barrett's mucosa, may be implicated in the development of adenocarcinoma of the oesophagus.
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In addition, recent reports have suggested that the degree and type of oncogene expression in some tumours (breast, ovary, pancreatic, stomach, and colon) may have prognostic importance. "15 Oncogenes Negative control sections for each oncogene were processed immunohistochemically without the primary antibody.
Immunohistochemical staining of cell membranes (C-erbB2, C-src), cytoplasm (c-ras), or nucleus (c-myc, c-fos, c-jun and p53) was scored by assessing both the intensity of staining and the proportion of cells stained, based on a modification of the technique of Corbett et al.2' Cytoplasmic staining was not considered to be positive for the purposes of semi-quantitation of c-erbB2. When cytoplasmic c-erbB2 staining was present it was noted separately (Table I) .
Briefly, intensity was scored on a four point scale: no staining=0; weak staining=+; moderate staining= + +; and intense staining= + + +. The proportion of cells staining was also scored on a four point scale: no cells staining= 0; 1-39% staining =1; 40-69% staining= II; 70-100% staining=III.
Two individuals assessed each section and there was complete agreement in 95% of cases with regard to the intensity and pattern of staining. In the few sections in which scores differed, the two observers agreed a common score. 20 [I]
(++) 13 [I] CB1 1) showed both membranous distribution and minimal cytoplasmic staining in most positive cells. C-erbB2 cytoplasmic staining was not included in the assessment of staining density; this included only membranous staining as suggested previously.2' C-src showed predominantly cytoplasmic distribution with minimal membranous staining. Similarly, c-ras and c-jun had a cytoplasmic pattern of reactivity whereas c-fos and p53 were both nuclear (Table  I) . C-myc failed to react positively with any of the sections under study, although a control section of lymph node containing lymphoma showed positive staining (Table II) .
The density of staining for all oncogenes was variable throughout the sections (Table II) . The staining pattern also varied from one cancer to another and one section of Barrett's oesophagus to another.
The proportion of cells positively stained also varied from one section to another, but to a lesser degree. carcinomas and 14% of Barrett's oesophagus (both of the latter had intestinal metaplasia). Csrc (Fig 3) was expressed in 20% of oesophageal carcinomas and also of Barrett's oesophagus (2 of 3 patients had intestinal metaplasia). One case of healthy gastric mucosa also expressed c-src weakly in the cytoplasm of epithelial cells.
NUCLEAR ONCOGENES
C-myc was not demonstrated in any oesophageal sections. C-fos (Fig 4) was found in one case of Barrett's oesophagus (gastric type metaplasia). C-jun (Fig 5) The present study has shown a very high incidence of membranous erbB2 expression in both malignant and Barrett's oesophageal tissue (73% expression and 60%, respectively) compared with the lower frequency of expression in other gastrointestinal cancers (gastric 30% and colonic 50%).`11727 30 This finding is interesting because we have recently reported an increased expression of epidermal growth factor receptors (EGF-R), which also have tyrosine kinase activity, in both oesophageal cancer and Barrett's epithelium.'6 However, the COOH domain of EGF-R and c-erbB2 exert different transforming activity,3' The erbB2 COOH domain has a positive stimulatory effect on erbB2 oncogenic activity, perhaps accounting for the fact that tumours expressing erbB2 have both a poorer short term (<5 years) as well as long term (> 10 years) prognosis. 16 12 16721 Moreover, tumours with erbB2 expression have been reported to metastasise readily.' 16 In this context, we have shown a paucity of c-erbB2 expression in epithelial membranes in normal gastric mucosa, with greater levels found in Barrett's oesophagus and the greatest levels of c-erbB2 expression on oesophageal carcinomas. In this respect membranous c-erbB2 expression is a marker for malignant potential, however, it has been suggested that cytoplasmic c-erbB2 expression, noted also in six sections of adenocarcinoma, may have less prognostic importance than membranous expression. " Whether this staining 16ankowski, Coghill, Hopwood, Wornnsley represents extracellular domain fragment secreted by native c-erbB gene is uncertain.T here are many possible methods by which wild type p53 could result in growth suppression,' j3 however, one recently reported mechanism is by selective down regulation of expression of the proliferating cell nuclear antigen.33 Therefore wild type p53 seems to exert essential inhibitory effects on cell proliferation, and therefore mutation of p53 may result in deregulation of cellular proliferation. Mutant p53 was shown in a similar proportion of sections of oesophageal adenocarcinoma (46%) compared with previous reports of other alimentary tumours (colonic carcinoma 33%). 1434 35 We were unable to demonstrate unequivocal p53 staining in (premalignant) Barrett's mucosa, irrespective of the presence or absence of dysplasia.'4 However, unlike erbB2, expression of which develops early in the neoplastic process, p53 mutation is usually a late step in carcinogenesis.""4 It is possible that the failure of this regulatory 'antioncogene' results in unopposed growth stimulation by the EGF-R and erbB2 receptor which is 'normally limited' in the nucleus by p53. 36 We anionoen,ifi ocr a ll ayrprsn f~~~~~alt tpi hedvlpeto eohga suggests that the oncogene and an abnormal antioncogene may also be important in the development of oesophageal adenocarcinoma. 49 We are presently assessing the prognostic potential of these oncogenes, especially since the incidence of adenocarcinoma is inceasing in Tayside. 5' adenocarcinoma of the oesophagus.
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